Drug
Molindone clinical trials
Also written SPN-810.
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2008 | 1 |
| 2011 | 2 |
| 2016 | 3 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 1
Supernus Pharmaceuticals, Inc. (8) · University of North Carolina, Chapel Hill (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antipsychotic Agents source
Studies
Open first, then newest update. How each study uses Molindone is read from its arms, and is right about nine times in ten.
Testing it · 9
- Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct ProblemsCompletedPhase 2Supernus Pharmaceuticals, Inc.NCT00626236Written as SPN-810
- Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHDTerminatedPhase 2Supernus Pharmaceuticals, Inc.NCT03638466Written as SPN-810
- Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)TerminatedPhase 3Supernus Pharmaceuticals, Inc.NCT02691182Written as SPN-810
- Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD TreatmentTerminatedPhase 3Supernus Pharmaceuticals, Inc.NCT03597503Written as SPN-810
- Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)CompletedPhase 3Supernus Pharmaceuticals, Inc.NCT02618434Written as SPN-810 (18 mg)
- Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)CompletedPhase 3Supernus Pharmaceuticals, Inc.NCT02618408Written as SPN-810 (18 mg)
- A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedPhase 2Supernus Pharmaceuticals, Inc.NCT01364662Written as SPN-810
- Open-Label, Extension Study to 810P202CompletedPhase 2Supernus Pharmaceuticals, Inc.NCT01416064Written as Molindone
- Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)CompletedPhase 4University of North Carolina, Chapel HillNCT00053703Written as Molindone
Codes
What other systems call Molindone · ClinicalTrials.gg INT007849
- MeSH (NLM) D008972MolindoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) RT3Y3QMF8NMOLINDONEConfirmed FDA, NLM, Wikidata
- RxNorm 7019Confirmed FDA, Wikidata
- Wikidata Q593166(±)-molindoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61850MolindoneOne source FDA
- DrugBank DB01618One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D008972 | Molindone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | RT3Y3QMF8N | MOLINDONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 7019 | — | Confirmed FDA, Wikidata |
| Wikidata | Q593166 | (±)-molindone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61850 | Molindone | One source FDA |
| DrugBank | DB01618 | — | One source Wikidata |
Also registered as molindone hydrochloride (UNII 1DWS68PNE6 · RxNorm 82051).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.